Status:

UNKNOWN

Normative Oculomotor and Vestibular Data in Pediatric Population

Lead Sponsor:

Neurolign

Collaborating Sponsors:

Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)

University of Miami

Conditions:

Healthy

Eligibility:

All Genders

6-18 years

Phase:

NA

Brief Summary

The purpose of this study is to use a device called I-Portal® Portable Assessment System (I-PAS) to record eye movements in response to a number of visual and auditory stimuli designed to evaluate neu...

Eligibility Criteria

Inclusion

  • Males or females age 6 to 18 years of all races.
  • Parental/guardian permission (informed consent) and child assent

Exclusion

  • History of head injury characterized by any of the following:
  • Resulting from penetrating trauma
  • Resulting from an automobile accident with significant associated injuries
  • Associated with a Glasgow Comma Scale Score of less than 13 at the time of injury
  • Associated with a loss of consciousness period greater than 30 minutes
  • Judged to be more than mild by medical staff
  • Requiring admission to the hospital for any reason
  • Associated with subdural or epidural hemorrhage
  • Persons with a previous history of mTBI in the past and who were symptomatic prior to current injury
  • Pregnancy, as documented by last menstrual period at study visits
  • Implants: Persons implanted with an electrical and/or neurostimulator device, including but not limited to cardiac pacemaker, defibrillator, vagal neurostimulator, deep brain stimulator, spinal stimulator, bone growth stimulator, or cochlear implant, metal cervical spine hardware
  • Diagnosed with attention deficit hyperactivity disorder (ADHD), autism spectrum disorder, major depression, hypochondriasis, bipolar disorders, or schizophrenia.
  • Presence of severe aphasia or inability to follow commands and give independent responses
  • Documented neurodegenerative disorders (Multiple sclerosis, Parkinson's, Alzheimer's, Huntington)
  • Past history of seizures or convulsions
  • Prior disorders of hearing and balance including:
  • Meniere's disease
  • Multiple sclerosis
  • Vestibular neuritis
  • Vestibular schwannoma
  • Sudden sensorineural hearing loss
  • History of ear operation other than myringotomy and tube placement in the past
  • Acute or chronic disease of middle ear (infections, otitis)
  • History of cerebrovascular disorders including stroke, brainstem or cerebellar dysfunction within the last 3 months
  • Systemic disorders that include chronic renal failure, cirrhosis of the liver, autoimmune disease, heart disease, lung disease, severe arthritis, diabetes, hypertension
  • Repeated history of syncope
  • Past or concomitant treatment with ototoxic chemotherapy
  • Previous contraindicating surgeries at the discretion of the study physician
  • Aminoglycosides in the past 6 months given via systemic or transtympanic administration
  • Concomitant treatment with any of the followings within the last 24 hours prior to testing if more than 2 doses have been taken:
  • Antihistamines: e.g. diphenhydramine, cyclizine, dimenhydrinate, meclizine, hydroxyzine, promethazine,
  • For ADHD and narcolepsy: e.g. Concerta, Daytrana, Methylin, Ritalin, Ritalin LA, Metadate ER, Aptensio XR, Cotempla XR-ODT, QuilliChew ER, and Quillivant XR
  • For schizophrenia and other mental diseases: e.g. Phenothiazines
  • Specific antibiotics: e.g. ethambutol, gentamycin
  • Anticonvulsant medications: e.g. topiramate
  • Currently suffering from dehydration
  • History or suspicion of substance abuse or addiction
  • Acute alcohol intoxication
  • Playing professional sports at the Olympic/league level

Key Trial Info

Start Date :

April 1 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

August 31 2022

Estimated Enrollment :

600 Patients enrolled

Trial Details

Trial ID

NCT04107610

Start Date

April 1 2021

End Date

August 31 2022

Last Update

March 3 2021

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

University of Miami

Miami, Florida, United States, 33136

2

Allegheny Health Network

Pittsburgh, Pennsylvania, United States, 15212